The overall efficiency of the new crown vaccine in Koxing was 50.38%, and the number of cases of secondary infection with the mutant strain bespoke be | A week of progress in the study of the new crown

The overall effectiveness rate of the New Crown Vaccine in China was 50.38 percent Recently, the Butantan Institute in Brazil released the final report of the Kosing vaccine trial, and the results of the post-trial trials conducted in Brazil showed that the overall efficiency of the inactivated new crown vaccine developed by Sinovac in China was 50.38 percent.
vaccine had previously been reported to be 91.25 per cent effective (Turkey), 78 per cent (Brazil, 7 January) and 65 per cent (Indonesia).
Of these, 78 per cent of the effectiveness rates reported in Brazil on 7 January were clinically efficient, taking into account only cases with obvious symptoms and seeking medical help (31 in the placebo group, 7 in the vaccine group);
50.38 per cent overall efficiency is higher than the World Health Organization (WHO) threshold for vaccine use (50 per cent overall efficiency).
uk case of secondary infection with a mutant strain without significant immune impairment was reported on 9 January in a study published in Clinical Infectious Diseases.
patient was diagnosed with VOC-202012/01 of the new coronavirus strain B.1.1.1.7 eight months after the first infection.
is much more serious than when the first infection was mild.
based on current evidence, it is difficult to confirm whether the infection and the change in condition are due to a decrease in the patient's immunity, or the virus mutation caused by immune escape.
able to escape some of the antibodies produced by the vaccine, the emergence of a new coronavirus "escape mutant" in Africa recently found in South Africa, a variant of the new coronavirus "501.V2" found in a "escape mutant" virus (E484K), it has been confirmed that it can escape some of the antibodies produced by the vaccine.
, the E484K mutation was found to reduce antibody recognition and help the new coronavirus bypass the immune protection provided by previous infections or vaccinations.
, scientists are trying to confirm whether a virus containing the "E484K" mutation or a combination of other mutations will invalidate the vaccine.
can respond to the new coronavirus "escape mutation", the source of new progress in the antibody: Science January 12, published in a study published in Science, researchers have developed a new compound nanoantibodies, not only can block the new coronavirus into human cells, the results also show that even if the virus mutation, the compound antibody can still play a good effect.
the team obtained composite nanoantibodies that bind to the virus better than monosant nanoantibodies, and the mesoactive activity increased by more than 100 times.
results show that in cultured human cells, the combination of nanoantibodies can be more effective in preventing the spread of the virus between cells.
also tested a strain of the virus that mutated very quickly.
results show that nanoantibod combinations that target different tables can greatly reduce the likely resistance of viruses to escape mutations.
Japan's suicide rate changed during the new crown outbreak: a recent study published in Nature Human Behavior showed that japan's monthly suicide rate fell by 14% in the first five months of the new crown pneumonia pandemic, but rose by 16% in the second wave.
the data set used in the study covered the entire Japanese population, and found that suicide rates among women, children and adolescents increased even more in the second wave of outbreaks.
suggest that future suicide prevention strategies should take into account the factors that reduce suicide rates in the first wave of outbreaks and target specific populations for effective prevention.
Using Genomic Epidemiology to accurately track the source of the UK's new coronavirus transmission chain: Science recently published a study in Science that looked at the location and time coVID-19 was introduced to the UK during the first wave of the outbreak (March-June 2019).
also used information on epidemiological factors and travel data.
their results, more than 1,000 identifiable UK transmission lineees were established and co-disseminated in the UK before the blockade was imposed on 23 March 2020.
results suggest that genome tracking techniques can be used to accurately track individual virus transmission linee in time and space, which can be used at the regional, national and international levels to respond to future epidemics.
The new crown will eventually become a source of mild common cold: In a study published in Science on January 12th, researchers analyzed immunological and epidemiological data from endemic human coronavirus (HCoVs) and found that the body's immune response to infection is rapidly weakening, while the immune response to disease reduction can be preserved in the body over a long period of time.
Combined with immune-related groups, the researchers used models to retell the current severity of the new coronavirus and the nature of HCoVs and show that once endemic and first exposed to children, the new coronavirus may not be more toxic than the common cold.
the body is infected with the new coronavirus, it is able to continuously optimize the immune response to the virus Source: Nature, January 18, in a study published in Nature in the form of an "accelerated preview", researchers examined 87 people who were infected with the new coronavirus Long-term antibody immunity was studied in infected patients, who took samples 1.3 and 6.2 months after infection, detected mesoth antibody levels in the plasma, and analyzed memory B cell characteristics.
Researchers found a significant increase in the ability of monoclonal antibodies and new coronavirus at 6.2 months, and they believe that during the evolution of 1.3 months to 6.2 months, monoclonal antibodies produced by memory B cells were not only more mesothontic, but also more effective in identifying new coronavirus mutants.
"Science and Technology Guide" Public Number Source: Science and Technology Guide Public Number Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here